3月31日，礼来制药以78亿美元收购英国药企Centessa，包括约63亿美元首付款及价值约15亿美元的或有价值权。Centessa创立于2021年，核心研发聚焦食欲素受体2激动剂，该类药物主要用于治疗日间过度嗜睡及各类觉醒障碍；主要候选药物cleminorexton在针对1型发作性睡病、2型发作性睡病及特发性嗜睡症的二期临床研究中展现出同类最优潜力。交易预计2026年第三季度完成，尚待监管审批。
Изображение: Стрингер / РИА Новости
。关于这个话题，钉钉下载提供了深入分析
Should you proceed to a retailer from our platform and complete a purchase, we might receive a referral fee. This income aids in funding our operations but has no bearing on the topics we address, our coverage methods, or the final price for you. Our independent assessments are not financially incentivized for ZDNET or its writers. We adhere to stringent policies that guarantee our editorial material remains free from advertiser influence.，推荐阅读whatsapp网页版@OFTLOL获取更多信息
今日体育版词语连线完整分类：若需额外协助，今日谜题分类如下：
Что думаешь? Оцени!